The Food and Drug Administration (FDA) has approved Encelto (revakinagene taroretcel-lwey) for the treatment of macular telangiectasia type 2 (MacTel).

In addition to comparable BCVA levels, the researchers concluded that the PDS implant “provides effective, durable, and ...

Chronic stress may elevate AMD risk, suggesting that holistic interventions and psychotherapy may benefit some of these patients.

The US Food and Drug Administration (FDA) has approved revakinagene taroretcel-lwey (ENCELTO) from Neurotech Pharmaceuticals ...

Q4 2024 Earnings Call Transcript March 5, 2025 EyePoint Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.64 EPS, expectations were $-0.54. Tessa Romero – JPMorgan: Yigal ...

Q4 2024 Earnings Call Transcript March 3, 2025 Ocular Therapeutix, Inc. misses on earnings expectations. Reported EPS is ...

Announces several updates to enhance and accelerate AXPAXLI registrational program in wet AMD, potentially supporting label flexibility of 6-12 ...

Age-related macular (AMD) degeneration is a leading cause of vision impairment and blindness in the elderly population.

Optical Coherence Tomography (OCT) provides detailed images of the back of your eye without causing any discomfort. The ...

Clinical trials are underway to evaluate the efficacy of combination therapy (photodynamic therapy [PDT] and steroids in the Neovascular AMD, Peri-Ocular Corticosteroids and PDT [NAPP] study ...

and monitor patients with AMD and then treat them while monitoring their retina could be the key to effectively managing the dry form of the disease and preventing its progression to the wet form,” ...